Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of RAD101 In Participants With Suspected Recurrence Of Brain Metastases After Radiotherapy; RAD101 PET Demonstrated 93% Concordance With MRI Across All Evaluable Lesions, Meeting The Primary Endpoint
14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.The Company plans to advance RAD101 into
Radiopharm Theranostics tested a new medical scan (called RAD101) on 30 brain cancer patients and found it matched regular scans 93% of the time, which was their main goal. When a company hits its main goal in testing, it's a sign the treatment might work, so keep watching for more results coming later.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.